We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finds AstraZeneca’s Farxiga Falls Short for Type 1 Diabetes
FDA Finds AstraZeneca’s Farxiga Falls Short for Type 1 Diabetes
The FDA shot down AstraZeneca’s Farxiga (dapagliflozin) as an adjunct treatment to insulin for type 1 diabetes patients in a complete response letter to the company on Monday.